A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features.
Mark M ZakiZain M VirkDiego B LópezJenna KlubnickJared T AhrendsenHemant VarmaVasileios C KyttarisIlana AbelesPublished in: European journal of rheumatology (2021)
Statin-associated immune-mediated necrotizing myopathy (IMNM) is a rare presentation of a statin-associated myopathy. Patients usually present with muscle weakness and pain in the setting of statin use with elevated creatine kinase (CK) levels and a positive anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody. Muscle biopsies typically show necrosis, CD68+ macrophages, and minimal lymphocytes. We present a case of a 67-year-old woman who had 2 months of progressive weakness and bilateral lower extremity pain after initiating atorvastatin therapy with symptoms persisting after statin cessation. She was found to have high anti-HMGCR antibody titers, and the biopsy of the rectus femoris muscle showed a prominent endomysial inflammatory cell infiltrate with necrotic and regenerative fibers and an atypical extensive inflammatory infiltrate composed of both CD4+ helper T cells and CD8+ cytotoxic T cells. She showed symptom resolution and normalization of CK levels and inflammatory markers with treatment involving a prolonged prednisone taper and a brief course of azathioprine, which was stopped because of the adverse effects.
Keyphrases
- cardiovascular disease
- coronary artery disease
- late onset
- chronic pain
- skeletal muscle
- cell therapy
- protein kinase
- ultrasound guided
- pain management
- end stage renal disease
- oxidative stress
- newly diagnosed
- mesenchymal stem cells
- neuropathic pain
- ejection fraction
- nk cells
- single cell
- case report
- dendritic cells
- tyrosine kinase
- fine needle aspiration
- immune response
- type diabetes
- patient reported outcomes
- spinal cord injury
- peripheral blood
- prognostic factors
- combination therapy
- single molecule
- myasthenia gravis
- early onset
- replacement therapy